On disclosed figures, revenue was KRW 200 million in 2022 and KRW 27.5 billion in 2024, with no data for 2023. Revenue then fell to KRW 2.17 billion in 2025, down 92.1% year on year. Separate-basis results for the nine months to Q3 2025 pointed to lower anticancer technology-transfer revenue as the main driver.
Operating losses of KRW 11.5 billion in 2022 and KRW 13.4 billion in 2023 persisted before an operating profit of KRW 16.9 billion in 2024 turned the year positive. The company returned to an operating loss of KRW 7.26 billion in 2025, and its operating margin moved from 61.3% in 2024 to -334.4% in 2025.
Attributable net income turned positive at KRW 20 billion in 2024, then became an attributable net loss of KRW 9.73 billion in 2025. The 2024 attributable profit exceeded that year's operating profit, and the same year coincided with the 2024 out-licensing deal with the U.S. company.
Net income including non-controlling interests was KRW 20 billion in 2024 and a net loss of KRW 9.73 billion in 2025. Operating cash flow was KRW 22 billion in 2024 and minus KRW 3.34 billion in 2025.
Quarterly operating losses widened in 2026, from KRW 2 billion in Q4 2025 to KRW 2.19 billion in Q1 2026, KRW 2.92 billion in Q2 and KRW 3.35 billion in Q3. Quarterly revenue was KRW 725 million in Q1 2026 and KRW 596 million in Q3, with no Q2 figure.
Attributable net income was KRW 201 million in Q1 2026, but the company returned to a KRW 1.99 billion net loss in Q2 and a KRW 4.6 billion loss in Q3, which was narrower than the KRW 4.96 billion loss a year earlier. The attributable net loss for the last four quarters totals KRW 8.65 billion.